Bellevue Group Ag Sage Therapeutics, Inc. Transaction History

Bellevue Group Ag

$5.93 Billion
Q3 2024

A detailed history of Bellevue Group Ag transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Bellevue Group Ag holds 4,460,693 shares of SAGE stock, worth $25 Million. This represents 0.54% of its overall portfolio holdings.

Number of Shares

4,460,693

Previous 4,464,693 0.09%

Holding current value

$25 Million

Previous $48.5 Million 33.67%

% of portfolio

0.54%

Previous 0.81%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$7.02 - $13.08 $28,080 - $52,320	-4,000 Reduced 0.09%	4,460,693 $32.2 Million
Q2 2024 Aug 14, 2024	SELL	$10.58 - $17.9 $9,003 - $15,232	-851 Reduced 0.02%	4,464,693 $48.5 Million
Q1 2024 May 15, 2024	BUY	$18.62 - $26.95 $17.7 Million - $25.7 Million	952,193 Added 27.1%	4,465,544 $83.7 Million
Q3 2023 Nov 14, 2023	BUY	$16.75 - $48.98 $6.68 Million - $19.5 Million	398,976 Added 12.81%	3,513,351 $72.3 Million
Q2 2023 Aug 14, 2023	BUY	$40.65 - $59.54 $990,843 - $1.45 Million	24,375 Added 0.79%	3,114,375 $146 Million
Q1 2023 May 15, 2023	BUY	$37.27 - $46.57 $4.5 Million - $5.62 Million	120,722 Added 4.07%	3,090,000 $130 Million
Q4 2022 Feb 14, 2023	SELL	$32.2 - $43.61 $45,080 - $61,054	-1,400 Reduced 0.05%	2,969,278 $113 Million
Q3 2022 Nov 14, 2022	SELL	$32.28 - $43.27 $80,700 - $108,175	-2,500 Reduced 0.08%	2,970,678 $116 Million
Q2 2022 Aug 11, 2022	SELL	$27.52 - $37.99 $2.18 Million - $3.01 Million	-79,226 Reduced 2.6%	2,973,178 $96 Million
Q1 2022 May 13, 2022	SELL	$30.71 - $45.71 $5.39 Million - $8.03 Million	-175,600 Reduced 5.44%	3,052,404 $101 Million
Q4 2021 Feb 10, 2022	BUY	$37.06 - $47.11 $704,140 - $895,090	19,000 Added 0.59%	3,228,004 $137 Million
Q3 2021 Nov 12, 2021	BUY	$40.26 - $57.37 $34 Million - $48.5 Million	844,800 Added 35.73%	3,209,004 $142 Million
Q2 2021 Aug 12, 2021	BUY	$54.88 - $79.29 $30.4 Million - $43.9 Million	553,500 Added 30.57%	2,364,204 $134 Million
Q1 2021 May 12, 2021	BUY	$70.65 - $96.76 $17.2 Million - $23.5 Million	243,200 Added 15.52%	1,810,704 $136 Million
Q4 2020 Feb 16, 2021	SELL	$58.41 - $89.06 $700,920 - $1.07 Million	-12,000 Reduced 0.76%	1,567,504 $136 Million
Q3 2020 Nov 16, 2020	BUY	$41.13 - $62.45 $6.75 Million - $10.2 Million	164,000 Added 11.59%	1,579,504 $96.5 Million
Q2 2020 Aug 13, 2020	SELL	$25.95 - $43.15 $67,470 - $112,190	-2,600 Reduced 0.18%	1,415,504 $58.9 Million
Q1 2020 May 14, 2020	BUY	$26.15 - $77.24 $2.86 Million - $8.44 Million	109,250 Added 8.35%	1,418,104 $40.7 Million
Q4 2019 Feb 14, 2020	BUY	$60.18 - $154.77 $321,963 - $828,019	5,350 Added 0.41%	1,308,854 $94.5 Million
Q3 2019 Nov 14, 2019	SELL	$140.29 - $189.96 $2.51 Million - $3.4 Million	-17,900 Reduced 1.35%	1,303,504 $183 Million
Q2 2019 Aug 14, 2019	BUY	$157.85 - $183.09 $206 Million - $239 Million	1,305,104 Added 8006.77%	1,321,404 $242 Million
Q1 2019 May 15, 2019	BUY	$89.33 - $163.65 $509,181 - $932,805	5,700 Added 53.77%	16,300 $2.59 Million
Q4 2018 Feb 12, 2019	SELL	$81.94 - $139.71 $49,164 - $83,826	-600 Reduced 5.36%	10,600 $1.02 Million
Q3 2018 Nov 13, 2018	SELL	$138.11 - $169.04 $124,299 - $152,136	-900 Reduced 7.44%	11,200 $1.58 Million
Q2 2018 Aug 07, 2018	SELL	$140.36 - $175.76 $49,126 - $61,516	-350 Reduced 2.81%	12,100 $1.89 Million
Q1 2018 May 09, 2018	SELL	$152.15 - $192.33 $30,430 - $38,466	-200 Reduced 1.58%	12,450 $2.01 Million
Q4 2017 Feb 14, 2018	BUY	$60.72 - $167.34 $768,108 - $2.12 Million	12,650	12,650 $2.08 Million

Others Institutions Holding SAGE

# of Institutions

198

Shares Held

46.5M

Call Options Held

402K

Put Options Held

209K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $333M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Bellevue Group Ag with notifications on news.

Account

Bellevue Group Ag Sage Therapeutics, Inc. Transaction History